| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Weichselbaum Alan | Chief Financial Officer | C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVENUE, SUITE 1950 #1183, MIAMI | /s/ Alan Weichselbaum | 10 Jun 2025 | 0001435390 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | MIRA | Stock Options (right to buy) | 15 May 2025 | Common Stock | 75,000 | $1.18 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (37,500) of the options will vest six (6) months following May 19, 2025, and twenty-five thousand (37,500) of the Option will vest twelve (12) months following May 25, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date. |